TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04841915

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-Protein Diet
Description: Diet consisting of 25E% from assigned protein during eucaloric diet and 35E% from assigned protein during hypocaloric diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-Protein Diet
Description: Diet consisting of 25E% from assigned protein during eucaloric diet and 35E% from assigned protein during hypocaloric diet
Study: NCT05761951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by IV (vein)
Study: NCT06004674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovenox 40mg
Description: Enoxaparin is a blood thinner. It is approved for use in the prevention of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness; inpatient treatment of acute DVT with or without pulmonary embolism; outpatient treatment of acute DVT without pulmonary embolism; Prevention of ischemic complications of unstable angina and non-Q-wave myocardial infarction; treatment of acute ST-segment elevation myocardial infarction(STEMI) managed medically or with subsequent percutaneous coronary intervention. The use of Lovenox has been shown to be safe, and it has also been used widely off-label in pregnancy.
Study: NCT05942326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep GOALS
Description: Web-based interventions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Brochures from the American Academy of Sleep Medicine (e.g., sleep hygiene, sleep in women) and SNAP education connection (e.g., family-friendly activities, meal planning)
Study: NCT05912166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wakeful Spanish
Description: Wakeful Spanish is the Spanish-language version of Wakeful, a self-directed 9-week digital mindfulness course closely aligned with traditional 8-week Mindfulness-based Stress Reduction (MBSR) programs. Wakeful makes one new class available to users each week for 9 weeks. Users receive weekly email notifications from Wakeful informing them when a new class is available. Estimated class duration is 1-1.5 hours.~With Wakeful, users can -~1. Write what they observed during meditations.~2. Be guided by videos/audios through breathing exercises and gentle stretching.~3. See what others experienced and their tips for overcoming challenges.~4. Access videos/audios that explain how mindfulness benefits the body and mind.~5. Receive suggestions on meditations to do during the week~6. Set an intention for the week based on class content.
Study: NCT05630118

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHUTi Intervention
Description: Sleep Healthy Using the Internet (SHUTi) is a well-validated version of e-CBT-I comprised of 6 weekly educational modules and daily sleep diaries. Participants will have 9 weeks to complete 6 once-weekly educational cores. Cores consist of: insomnia overview, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention, and last approximately 45 minutes each. Participants will receive weekly objectives, as well as review and feedback on the previous core's assignments and sleep diary data, new material, assignments, and a summary. These features are supplemented with interactive features (i.e., personalized goal-setting, video vignettes). Participants receive daily emails prompting them to complete the 11-item sleep and alcohol use diary daily during the intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-Based Insomnia Education Program
Description: Participants will be given access to a web-based program on sleep education to read at their own pace during the 9-week intervention period. The program content overlaps with SHUTi on the following topics: insomnia symptoms, impacts, and causes, basic sleep improvement strategies, and when to see a doctor. The information is akin to that found on WebMD or National Sleep Foundation website. Unlike the SHUTi program, the information is fixed, accessible immediately (no week-to-week information unlocking) and there are no customized bedtime or wake-time suggestions based on sleep diary data.
Study: NCT05506631

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Outpatient Foley balloon placement
Description: Cervical ripening with balloon placement in the outpatient setting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient Foley Balloon placement
Description: Cervical ripening with balloon placement in the inpatient setting
Study: NCT04767646

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive rehabilitation program with CPNB
Description: The patient will have an intensive rehabilitation program (two 30-minute kinesitherapy sessions every day and 30-minute occupational therapy sessions 5 days a week) with the CPNB.~The patient will have follow-up consultation at 1 month, 3 month, 6 month and 1 year after the beggining of the intensive rehabilitation program
Study: NCT06255340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3031185
Description: BI 3031185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3031185
Description: BI 3031185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3031185
Description: BI 3031185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3031185
Description: BI 3031185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3031185
Description: BI 3031185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3031185
Description: BI 3031185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3031185
Description: BI 3031185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3031185
Description: BI 3031185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3031185
Description: BI 3031185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3031185
Description: BI 3031185

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 3031185
Description: Placebo
Study: NCT06151665

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single file rotary
Description: Kedo-S plus file is the fifth generation of pediatric files will be used in pulpectomy of primary molars

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Manual K files
Description: Stainless-steel K files is the golden standard files used in pulpectomy of primary molars
Study: NCT04841915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical dietician
Description: Counselling from a clinical dietician bi-weekly until weight loss of 5% is achieved.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Clinical dietician
Description: Counselling from a clinical dietician bi-weekly until weight loss of 5% is achieved.
Study: NCT04228003

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pendulum Glucose Control formulation for T2D
Description: All bacteria contained in the study product formulation are commensal organisms that have been repeatedly documented to inhabit the human GI tract under normal circumstances. Pendulum's Glucose Control Formulation consists of five human commensal microbial strains including butyrate producing and mucin-degrading strains. The organisms were grown under controlled conditions consistent with Good Manufacturing Practices (GMP) and employ no animal-derived products. All ingredients utilized during manufacturing were food grade and qualified as generally recognized as safe (GRAS).~The product is provided as acid-resistant capsules in bottles that are to be stored refrigerated at 4℃.
Study: NCT04743063

Intervention type: DRUG
Intervention: sacubitril/valsartan
Description: Initiation of sacubitril/valsartan, identified using prescription fill in pharmacy claims

Intervention type: DRUG
Intervention: Angiotensin II Receptor Blockers
Description: Initiation of ARBs, identified using prescription fill in pharmacy claims
Study: NCT04841915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical dietician
Description: Counselling from a clinical dietician bi-weekly until weight loss of 5% is achieved.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss
Description: 4 weeks eucaloric diet \~13 MJ/day followed by, 20 weeks hypocaloric diet \~9 MJ/day until 5% weight loss is achieved.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Weight loss
Description: 4 weeks eucaloric diet \~13 MJ/day followed by, 20 weeks hypocaloric diet \~9 MJ/day until 5% weight loss is achieved.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss
Description: 4 weeks eucaloric diet \~13 MJ/day followed by, 20 weeks hypocaloric diet \~9 MJ/day until 5% weight loss is achieved.
Study: NCT04849325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)
Description: Subjects in this arm will be treated with IBS Titan™.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA) Device
Description: Subjects in this arm will be treated with PTA device.
Study: NCT05333783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Reality Exposure Therapy Based on ExposXR software
Description: The ExposXR software is developed by The Stress Trauma Anxiety Research Clinic at Wayne State University, U.S.A. When it is used inside a Augmented Reality hardware such as Hololens, it renders artificial phobic objects into what the participants see. The treatment consist of a one-session treatment for cynophobia using Augmented Reality.
Study: NCT05826184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restircted eating
Description: 8 hour time restricted eating alone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating + prebiotic
Description: 8 hour TRE with a prebiotic supplement
Study: NCT05730478

Intervention type: DEVICE
Intervention: ASOCT&UBM
Description: glaucoma assesment by ASOCT \&UBM

Intervention type: DRUG
Intervention: Glaucoma therapy
Description: ASOCT and UBM parameters Comparison

Intervention type: DRUG
Intervention: Glaucoma therapy
Description: Comparison
Study: NCT04652765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camostat Mesilate
Description: Camostat 600mg by mouth four times a day, for a total of 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camostat Mesilate
Description: Camostat 600mg by mouth four times a day, for a total of 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide 150 mg
Description: Bicalutamide 150mg by mouth once daily, for a total of 7 days
Study: NCT06592521

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTI-FREE EXPRESS MPDS and Alcon contact lens case
Description: Multi-purpose disinfecting solution (MPDS) used for cleaning, disinfecting, and storage of soft contact lenses; commercially available in country of conduct.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTI-FREE PureMoist MPDS and Alcon contact lens case
Description: Multi-purpose disinfecting solution (MPDS) used for cleaning, disinfecting, and storage of soft contact lenses; commercially available in country of conduct.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTI-FREE REPLENISH MPDS and Alcon contact lens case
Description: Multi-purpose disinfecting solution (MPDS) used for cleaning, disinfecting, and storage of soft contact lenses; commercially available in country of conduct.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Habitual contact lenses
Description: Daily wear, reusable, soft (including hydrogel and silicone hydrogel) contact lenses according to subject's habitual prescription worn in both eyes and removed prior to sleep for cleaning and disinfection with the study product provided.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Habitual contact lenses
Description: Daily wear, reusable, soft (including hydrogel and silicone hydrogel) contact lenses according to subject's habitual prescription worn in both eyes and removed prior to sleep for cleaning and disinfection with the study product provided.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Habitual contact lenses
Description: Daily wear, reusable, soft (including hydrogel and silicone hydrogel) contact lenses according to subject's habitual prescription worn in both eyes and removed prior to sleep for cleaning and disinfection with the study product provided.
Study: NCT05148663

Intervention type: DIAGNOSTIC_TEST
Intervention: CCM Hemorrhagic Panel
Description: Biomarker

Intervention type: DIAGNOSTIC_TEST
Intervention: CCM Hemorrhagic Panel
Description: Biomarker
Study: NCT06608732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inaticabtagene autoleucel
Description: CNCT19 combined with autologous hematopoietic stem cell transplantation，Dose: （0.5 -2）x 10\^6/kg CNCT19 Cell Injection via intravenous infusion.
Study: NCT06606600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Kebbi robot interventions
Description: The intensive Kebbi robot interventions will receive 30 minutes, 3 times per week for 12 weeks.
Study: NCT06663969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temporal Interference
Description: Researchers applied temporal interference (TI) stimulation to the deep brain nuclei of patients who had undergone SEEG monitoring, recording changes in electrical activity detected by SEEG.
Study: NCT06606158

Intervention type: OTHER
Intervention: Exercises program
Description: Strength, mobility, and balance exercises described within the standardized Physiotherapy plan.

Intervention type: OTHER
Intervention: App exercises program
Description: A strength, mobility, and balance exercise program delivered through a mobile app.
Study: NCT05700422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Nasal Spray
Description: OC-01 (varenicline solution) 0.03 mg nasal spray
Study: NCT06673043

Intervention type: DRUG
Intervention: Anifrolumab
Description: Anifrolumab 300 mg concentrate for solution for infusion
Study: NCT06314152

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lightweight mesh fixation in 3 points or 1 point
Description: Lightweight mesh fixation in 3 points

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lightweight mesh fixation in 3 points or 1 point
Description: Lightweight mesh fixation in 3 points
Study: NCT06673979

Intervention type: DIAGNOSTIC_TEST
Intervention: Numeric Rating Scale
Description: The patients are asked to rate their pain according to the Numeric Rating Scale (0=no pain; 10=worse possible pain).

Intervention type: DIAGNOSTIC_TEST
Intervention: Numeric Rating Scale
Description: The patients are asked to rate their pain according to the Numeric Rating Scale (0=no pain; 10=worse possible pain).
Study: NCT06674759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tongren-Dahuoluo Bolus
Description: 0.72g,2 times a day, oral, for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tongren-Dahuoluo Bolus Placebo
Description: 0.72g,2 times a day, oral, for 12 weeks.
Study: NCT06679504

Intervention type: PROCEDURE
Intervention: Fibrin glue fixation
Description: Laparoscopic Totally Extraperitoneal Inguinal Hernia Repair With Fibrin Glue fixation

Intervention type: PROCEDURE
Intervention: Tack fixation
Description: Laparoscopic Totally Extraperitoneal Inguinal Hernia Repair With Tack Mesh Fixation
Study: NCT06679517

Intervention type: PROCEDURE
Intervention: TAVI
Description: Clinical follow-up up to 10 years of patients undergoing TAVI
Study: NCT06674876

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Blog writing
Description: Participants were asked to write 2blogs online for four weeks and attend a 4hours wellness workshop

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Blog writing
Description: Participants were asked to write 2blogs online for four weeks and attend a 4hours wellness workshop
Study: NCT05369260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation-based cervical and scapular stabilization exercises
Description: Telerehabilitation based cervical and scapular stabilization exercises will be applied via videoconference method for 8 weeks, one day a week , 45-60 minutes for each session.
Study: NCT06675708

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: From the total sample obtained after recruitment, randomization will be performed using the SPSS statistical program, creating two groups. One experimental group will receive creatine supplementation, and the other group will receive a placebo through dextrose administration. In both cases, the doses will be administered in the same manner to both groups

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose
Description: From the total sample obtained after recruitment, randomization will be performed using the SPSS statistical program, creating two groups. Dextrose group will be administered in the same manner as creatine to the experimental group. The doses will be prepared in the same way for both groups.
Study: NCT06675877

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: virtual reality camera
Description: The virtual reality eyeglasses were placed on the child's head, the child watched 3 D VR kids' cartoons or videos to distract his/her attention during needle insertion. The video was displayed through a smart phone inserted inside the virtual reality headset.
Study: NCT06675448

Intervention type: DEVICE
Intervention: MitraClip
Description: Participants will undergo the Mitraclip procedure according to current standards of practice

Intervention type: OTHER
Intervention: Moderate MR
Description: Patients who present with moderate MR (Mitral regurgitation) will serve also as an internal control against which the outcomes of Mitraclip treated patients)
Study: NCT06674369

Intervention type: DEVICE
Intervention: Peli prism for hemianopia
Description: Peli prism uses high-powered prisms (40 Dioptre) that expand a hemianopic patient's awareness of their blind side. This awareness enables patients to better detect obstacles and navigate around them. Effect of the prism considered as temporary We investigated whether the effect persists after the prism is removed.To understand the persistence of the effect, we examined the changes in the visual field with CVF (Computerized visual field examination)before the prism was applied, with the prism and 1 week after the prism was removed.
Study: NCT06675214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Full course of PD-1/PD-L1 blockades
Description: a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full course of PD-1/PD-L1 blockades
Description: a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin-based induction chemotherapy
Description: Cisplatin-based induction chemotherapy will be given every 3 weeks for 3 cycles before radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin-based induction chemotherapy
Description: Cisplatin-based induction chemotherapy will be given every 3 weeks for 3 cycles before radiotherapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard-dose IMRT
Description: GTVnx/nd:69.96Gy/33Fr/2.12Gy CTV1: 60.60Gy/33Fr/1.82y CTV2: 54.12Gy/33Fr/1.64Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gradient Fractionated IMRT
Description: GTVresidue: 68Gy/30Fr/2.27Gy GTVmcr: 60Gy/30F/2Gy CTV1:54Gy/30F/1.8Gy CTV2: 48GY/30F/1.60Gy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent Chemotherapy
Description: Cisplatin 100mg/m2 every 3 weeks for 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent Chemotherapy
Description: Cisplatin 100mg/m2 every 3 weeks for 2 cycles
Study: NCT05371470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ellipsis Health Voice Application
Description: Smartphone application that utilizes voice biomarkers to assess for potential presence and severity of depression and anxiety
Study: NCT06679907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WaveLinQ® device
Description: The WaveLinQ® system employs a dual catheter technique to establish communication between deep arteries and veins, typically using a ulnar or radial artery and vein. This procedure necessitates fluoroscopic guidance to position the catheters correctly, a control angiogram, and potential embolization to enhance blood flow.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ellipsys® device
Description: The Ellipsys® system enables the entire AVF creation process to be conducted under ultrasound guidance without the need for fluoroscopy or contrast media. It uses a single needle to puncture the superficial vein, the perforator and the artery and potential balloon angioplasty to enhance blood flow.
Study: NCT05369260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation-based cervical and core stabilization exercises
Description: Telerehabilitation based cervical and core stabilization exercises will be applied via videoconference method for 8 weeks, one day a week , 45-60 minutes for each session.
Study: NCT06679907

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No device
Description: Surgical AVF creation will involve a direct approach to the proximal radial, ulnar, or brachial artery to create a 4-6 mm longitudinal arteriotomy. An oblique incision will be made at the elbow crease. The cephalic, basilic, or perforating vein may be used for the side-to-end anastomosis. If a transposition is required due to adiposity, it will be performed either during the same procedure or at a later time through tunneling or lipectomy.
Study: NCT06231836

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula (HFNO)
Description: O2 is administered by HFNO with flow 70L/min and the FiO2 is set at 40%,
Study: NCT06686862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: Ibuprofen tapering schedule during 3 weeks. First week: Ibuprofen 600 mg every 8 hours. Second week: Ibuprofen 600 mg every 12 hours. Third week: Ibuprofen 600 mg every 24 hours.